ID

40428

Descripción

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01495247

Link

https://clinicaltrials.gov/show/NCT01495247

Palabras clave

Versiones (1)
  1. 20/4/20 20/4/20 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

20 de abril de 2020

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Inoperable Locally Advanced Breast Cancer NCT01495247

Inglés

Eligibility Inoperable Locally Advanced Breast Cancer NCT01495247

1 formularios  
Criteria
Descripción

Criteria

females with breast cancer that is histologically or cytologically confirmed, her2 negative and locally advanced or metastatic as confirmed by radiology
Descripción

Gender | Breast Carcinoma HER2 Negative Advanced Locally | Secondary malignant neoplasm of female breast

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2,1]
C0678222
UMLS CUI [2,2]
C2348908
UMLS CUI [2,3]
C0205179
UMLS CUI [2,4]
C1517927
UMLS CUI [3]
C0346993
ecog performance status 0 and 1
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
adequate bone marrow and organ function
Descripción

Bone Marrow function | Organ function

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0678852
exclusion criteria (phase lb):
Descripción

Exclusion Criteria

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0680251
previous treatment with pi3k and/or mtor inhibitors
Descripción

PI3K Inhibitor | mTOR Inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1519050
UMLS CUI [2]
C2746052
symptomatic central nervous system (cns) metastases
Descripción

CNS metastases Symptomatic

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0231220
concurrent malignancy or malignancy in the last 5 years prior to start of study treatment
Descripción

Malignant Neoplasms

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
wide field radiotherapy ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to starting study drug
Descripción

Therapeutic radiology procedure Field Wide | Palliative course of radiotherapy Field Limited

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C1882536
UMLS CUI [1,3]
C0332464
UMLS CUI [2,1]
C0475092
UMLS CUI [2,2]
C1882536
UMLS CUI [2,3]
C0439801
active cardiac disease (e.g. lvef less than institutional lower limit of normal, qtcf > 480 msec, unstable angina pectoris, ventricular, supraventricular or nodal arrhythmias)
Descripción

Heart Disease | Left ventricular ejection fraction | QTcF Prolongation | Angina, Unstable | Ventricular arrhythmia | Supraventricular arrhythmia | Nodal rhythm disorder

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2]
C0428772
UMLS CUI [3]
C3828431
UMLS CUI [4]
C0002965
UMLS CUI [5]
C0085612
UMLS CUI [6]
C0428974
UMLS CUI [7]
C0264893
inadequately controlled hypertension
Descripción

Poor hypertension control

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0421190
impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of bez235 and/or paclitaxel
Descripción

Abnormal digestive tract function | Gastrointestinal Disease Changing Absorption BEZ235 | Gastrointestinal Disease Changing Absorption Paclitaxel

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0232459
UMLS CUI [2,1]
C0017178
UMLS CUI [2,2]
C0392747
UMLS CUI [2,3]
C0237442
UMLS CUI [2,4]
C2347425
UMLS CUI [3,1]
C0017178
UMLS CUI [3,2]
C0392747
UMLS CUI [3,3]
C0237442
UMLS CUI [3,4]
C0144576
treatment at start of study treatment with drugs with a known risk to induce torsades de pointes, moderate and strong inhibitors or inducers of isoenzyme cyp3a4, warfarin and coumadin analogues, lhrh agonists
Descripción

Pharmaceutical Preparations At risk Torsades de Pointes | CYP3A4 Inhibitors Moderate | CYP3A4 Inhibitors Strong | CYP3A4 Inducers Moderate | CYP3A4 Inducers Strong | Warfarin Analogue | Coumadin Analogue | Luteinizing Hormone-releasing Hormone Agonist

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1444641
UMLS CUI [1,3]
C0040479
UMLS CUI [2,1]
C3850053
UMLS CUI [2,2]
C0205081
UMLS CUI [3,1]
C3850053
UMLS CUI [3,2]
C0442821
UMLS CUI [4,1]
C3850041
UMLS CUI [4,2]
C0205081
UMLS CUI [5,1]
C3850041
UMLS CUI [5,2]
C0442821
UMLS CUI [6,1]
C0043031
UMLS CUI [6,2]
C0243071
UMLS CUI [7,1]
C0699129
UMLS CUI [7,2]
C0243071
UMLS CUI [8]
C1518041
sensitivity to paclitaxel treatment
Descripción

Paclitaxel allergy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0570707
uncontrolled diabetes mellitus
Descripción

Diabetic - poor control

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0421258
pregnant or nursing (lactating) woman
Descripción

Pregnancy | Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
other protocol-defined inclusion/exclusion criteria may apply
Descripción

Eligibility Criteria Additional

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C1524062
Volver a la parte superior de la página

Similar models

Eligibility Inoperable Locally Advanced Breast Cancer NCT01495247

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Gender | Breast Carcinoma HER2 Negative Advanced Locally | Secondary malignant neoplasm of female breast
Item
females with breast cancer that is histologically or cytologically confirmed, her2 negative and locally advanced or metastatic as confirmed by radiology
boolean
C0079399 (UMLS CUI [1])
C0678222 (UMLS CUI [2,1])
C2348908 (UMLS CUI [2,2])
C0205179 (UMLS CUI [2,3])
C1517927 (UMLS CUI [2,4])
C0346993 (UMLS CUI [3])
ECOG performance status
Item
ecog performance status 0 and 1
boolean
C1520224 (UMLS CUI [1])
Bone Marrow function | Organ function
Item
adequate bone marrow and organ function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0678852 (UMLS CUI [2])
Exclusion Criteria
Item
exclusion criteria (phase lb):
boolean
C0680251 (UMLS CUI [1])
PI3K Inhibitor | mTOR Inhibitor
Item
previous treatment with pi3k and/or mtor inhibitors
boolean
C1519050 (UMLS CUI [1])
C2746052 (UMLS CUI [2])
CNS metastases Symptomatic
Item
symptomatic central nervous system (cns) metastases
boolean
C0686377 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
Malignant Neoplasms
Item
concurrent malignancy or malignancy in the last 5 years prior to start of study treatment
boolean
C0006826 (UMLS CUI [1])
Therapeutic radiology procedure Field Wide | Palliative course of radiotherapy Field Limited
Item
wide field radiotherapy ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to starting study drug
boolean
C1522449 (UMLS CUI [1,1])
C1882536 (UMLS CUI [1,2])
C0332464 (UMLS CUI [1,3])
C0475092 (UMLS CUI [2,1])
C1882536 (UMLS CUI [2,2])
C0439801 (UMLS CUI [2,3])
Heart Disease | Left ventricular ejection fraction | QTcF Prolongation | Angina, Unstable | Ventricular arrhythmia | Supraventricular arrhythmia | Nodal rhythm disorder
Item
active cardiac disease (e.g. lvef less than institutional lower limit of normal, qtcf > 480 msec, unstable angina pectoris, ventricular, supraventricular or nodal arrhythmias)
boolean
C0018799 (UMLS CUI [1])
C0428772 (UMLS CUI [2])
C3828431 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0085612 (UMLS CUI [5])
C0428974 (UMLS CUI [6])
C0264893 (UMLS CUI [7])
Poor hypertension control
Item
inadequately controlled hypertension
boolean
C0421190 (UMLS CUI [1])
Abnormal digestive tract function | Gastrointestinal Disease Changing Absorption BEZ235 | Gastrointestinal Disease Changing Absorption Paclitaxel
Item
impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of bez235 and/or paclitaxel
boolean
C0232459 (UMLS CUI [1])
C0017178 (UMLS CUI [2,1])
C0392747 (UMLS CUI [2,2])
C0237442 (UMLS CUI [2,3])
C2347425 (UMLS CUI [2,4])
C0017178 (UMLS CUI [3,1])
C0392747 (UMLS CUI [3,2])
C0237442 (UMLS CUI [3,3])
C0144576 (UMLS CUI [3,4])
Pharmaceutical Preparations At risk Torsades de Pointes | CYP3A4 Inhibitors Moderate | CYP3A4 Inhibitors Strong | CYP3A4 Inducers Moderate | CYP3A4 Inducers Strong | Warfarin Analogue | Coumadin Analogue | Luteinizing Hormone-releasing Hormone Agonist
Item
treatment at start of study treatment with drugs with a known risk to induce torsades de pointes, moderate and strong inhibitors or inducers of isoenzyme cyp3a4, warfarin and coumadin analogues, lhrh agonists
boolean
C0013227 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0040479 (UMLS CUI [1,3])
C3850053 (UMLS CUI [2,1])
C0205081 (UMLS CUI [2,2])
C3850053 (UMLS CUI [3,1])
C0442821 (UMLS CUI [3,2])
C3850041 (UMLS CUI [4,1])
C0205081 (UMLS CUI [4,2])
C3850041 (UMLS CUI [5,1])
C0442821 (UMLS CUI [5,2])
C0043031 (UMLS CUI [6,1])
C0243071 (UMLS CUI [6,2])
C0699129 (UMLS CUI [7,1])
C0243071 (UMLS CUI [7,2])
C1518041 (UMLS CUI [8])
Paclitaxel allergy
Item
sensitivity to paclitaxel treatment
boolean
C0570707 (UMLS CUI [1])
Diabetic - poor control
Item
uncontrolled diabetes mellitus
boolean
C0421258 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant or nursing (lactating) woman
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Eligibility Criteria Additional
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C1516637 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial